Proportions of patients achieving DAS28-ESR remission at week 24 and week 52
| Placebo+MTX n=287 | 4 mg/kg TCZ+MTX n=288 | 8 mg/kg TCZ+MTX n=290 | 8 mg/kg TCZ+placebo n=292 | |
|---|---|---|---|---|
| Week 24 | ||||
| Responders, n (%) (95% CI) | 43 (15.0) (10.9 to 19.1) | 92 (31.9) (26.6 to 37.3) | 130 (44.8) (39.1 to 50.6) | 113 (38.7) (33.1 to 44.3) |
| p Value vs placebo+MTX | <0.0001* | <0.0001 | <0.0001 | |
| OR (95%) relative to placebo+MTX | 2.72 (1.80 to 4.11) p<0.0001* | 4.77 (3.19 to 7.14) p<0.0001 | 3.70 (2.47 to 5.55) p<0.0001 | |
| Week 52 | ||||
| Responders, n (%) (95% CI) | 56 (19.5) (14.9 to 24.1) | 98 (34.0) (28.6 to 39.5) | 142 (49.0) (43.2 to 54.7) | 115 (39.4) (33.8 to 45.0) |
| p Value vs placebo+MTX | <0.0001* | <0.0001 | <0.0001* | |
ORs were determined by logistic regression analysis.
*The comparison occurred after a break in the hierarchically ordered testing sequence.
DAS28, Disease Activity Score using 28 joints; ESR, erythrocyte sedimentation rate; MTX, methotrexate; TCZ, tocilizumab.